Sparrow Pharmaceuticals to Present New Pharmacology Data on SPI-62 at the 2022 Annual European Congress of Rheumatology
apnews.com
business
2022-06-01 15:36:29

PORTLAND, Ore.--(BUSINESS WIRE)--Jun 1, 2022--Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new pharmacology data at the 2022 Annual European Congress of Rheumatology (EULAR) on its lead candidate, SPI-62, an HSD-1 inhibitor. SPI-47, a fixed-dose-combination of SPI-62 and prednisolone, is being developed for autoimmune and inflammatory diseases beginning with polymyalgia rheumatica.
